AlphaYou
Overview
Smart money at a glance
Filings to Sep 27, 2026Net selling: insiders sold $67.8M and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $6K to $90K in total in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$67.8M netNet selling
- CongressSTOCK Act, last 180 days
- $6K to $90K tradedMixed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 6 added, 3 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- 10+ awardsAwards on record
Key stats
Fundamentals Sep 27- Open
- $271.70
- 52-wk high
- $281.07
- High
- $272.25
- 52-wk low
- $175.82
- Low
- $269.26
- Prev close
- $270.68
- Mkt cap
- $653.61B
- P/E
- 31.5x
- Volume
- 4.09M
- Fwd P/E
- 21.0x
- Beta
- 0.23
- Div yield
- 1.94%
- P/S
- 6.7x
- P/B
- 7.6x
- Profit margin
- +21.5%
- Op margin
- +29.2%
- ROE
- +25.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about JNJ filings
Are insiders buying or selling Johnson & Johnson (JNJ) stock?
Net selling: insiders sold $67.8M and bought $0 of JNJ stock on the open market in the 90 days to Sep 27, 2026, according to SEC Form 4 filings. The largest was Duato, Joaquin (CEO and Chairman of the Board), who sold $44.7M. The latest filing was on Sep 4, 2026.
Which members of Congress have traded JNJ recently?
Rep. Thomas H. Kean Jr sold $1K to $15K on Aug 27, 2026, disclosed 16 days later. Sen. John Boozman (R) sold $1K to $15K on Aug 20, 2026, disclosed 22 days later. Rep. Richard Dean McCormick (R) sold $1K to $15K on Jul 30, 2026, disclosed 15 days later. Rep. Thomas H. Kean Jr sold $1K to $15K on Jun 29, 2026, disclosed 16 days later. In total, 4 members disclosed 6 JNJ trades with trade dates in the last 180 days, filed a median 19 days after trading.
How current is this JNJ smart-money data?
This summary uses filings available on Sep 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- QR
Qube Research
$191.1M
bought
- SQ
Squarepoint
$138.5M
added
- MI
Millennium
$96.9M
added
What insiders are doing
What Congress is doing
How top traders are positioned
No tracked top-trader positions in JNJ right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 2.1% above what analysts expected.
Earnings per share
$2.84 expected
Revenue
No comparable estimate
FY2026 guidance
$100.80B to $101.40B
No comparable estimate
Reports Oct 13, 2026, in 16 days
Estimates as of Sep 27, 2026
EPS expected
$2.31 to $2.66
Revenue expected
6 analysts
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $23.99B | $24.56B | $24.06B | $25.31B |
| Cost of what it sold | $7.30B | $7.97B | $8.11B | $8.05B |
| Gross profit | $16.69B | $16.60B | $15.96B | $17.26B |
| What it spent | ||||
| Research and development | $3.67B | $4.25B | $3.53B | $3.65B |
| Sales and admin | $5.92B | $6.95B | $6.03B | $6.43B |
| Other operating costs | — | -$200.0M | — | — |
| Total operating expenses | $9.59B | $11.01B | $9.56B | $10.09B |
| What was left | ||||
| Operating profit | $7.10B | $5.59B | $6.39B | $7.17B |
| Interest on debt | $245.0M | $214.0M | $272.0M | $281.0M |
| Profit before tax | $7.49B | $4.97B | $5.99B | $6.75B |
| Tax | $2.34B | -$150.0M | $755.0M | $1.21B |
| Net profit | $5.15B | $5.12B | $5.24B | $5.53B |
| EBITDA | $9.29B | $7.19B | $8.27B | $8.99B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - What's Next?
Leans bullishSep 25Johnson & Johnson Clinical Trials Show Progress Across Key Therapies
BullishSep 25ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
Leans bullishSep 25What Bristol Myers Squibb Stock’s Strong Buy Upgrade Means For Shareholders
NeutralSep 25PepsiCo stock hits 52-week low at 127.55 USD
NeutralSep 25J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
BullishSep 25Rx Rundown: Lilly, Bristol Myers Squibb, Johnson & Johnson and more
Leans bearishSep 25Two Wilson County Grads Turn a Night Class Into Jobs at Johnson & Johnson's New Biologics Plant
NeutralSep 25
Macro
20 macro signals shaping JNJ right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results